Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Yoshiaki Amino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Lung Neoplasms, Adenocarcinoma, Mucinous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
KRAS mutation positive lung cancer is known to be clinically characterized by older age, males, and smokers. It is reported to be more common in mucinous adenocarcinoma, but all reports are based on analysis of tissue samples. Recently, blood samples have become available for analysis, suggesting a low detection rate of circulating tumor DNA in histological types, especially mucinous adenocarcinoma. In this study, we investigated the clinical characteristics of KRAS mutation‐positive cases in the analysis of blood specimens, as these remain unclear.
Methods
The clinical background of patients with KRAS mutation among those who underwent next‐generation sequencing (NGS) analysis using blood samples was evaluated.
Results
NGS analysis was performed on 214 blood samples. KRAS mutations were detected in blood samples in 33 cases (15.4%), of which 31 cases (14.5%) had a histological pathology diagnosis. Mucinous adenocarcinoma accounted for 28.6% of cases with positive blood and tissue specimens, 10.0% of cases with positive blood specimens only, and 57.1% of cases with positive tissue specimens only. Mucinous adenocarcinoma tended to be less common in cases with positive blood specimens. In KRAS ‐positive patients with lung metastasis only, only one nonmucinous adenocarcinoma had a positive blood sample, and the others all had mucinous adenocarcinomas with positive tissue samples only.
Conclusion
The results showed that the detection rate of KRAS ‐positive lung cancers detected by blood and tissue samples differs, and that the detection rate of blood samples may be poor, especially in the case of mucinous adenocarcinoma with lung metastases only.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
- Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Respiratory medicine, Jikei University School of Medicine, Tokyo, Japan.
- Department of Respiratory medicine, Hachinohe City Hospital, Hachinohe, Aomori, Japan.
ORCID-Profile: Yoshiaki Amino, Ken Uchibori, Makoto Nishio
Zitieren
APA
Amino, Y., Low, S. K., Ninomiya, H., Kiritani, A., Miyadera, K., Kakuto, S., Akita, T., Tsugitomi, R., Ariyasu, R., Uchibori, K., Kitazono, S., Yanagitani, N., & Nishio, M. (2023). Clinical characteristics of patients with KRAS mutation detected by liquid biopsy. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15123
Vancouver
Amino Y, Low SK, Ninomiya H, Kiritani A, Miyadera K, Kakuto S, et al. Clinical characteristics of patients with KRAS mutation detected by liquid biopsy. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15123
BibTeX
@article{Amino2023,
author = {Amino, Yoshiaki and Low, Siew-Kee and Ninomiya, Hironori and Kiritani, Ayu and Miyadera, Keiki and Kakuto, Sho and Akita, Takahiro and Tsugitomi, Ryosuke and Ariyasu, Ryo and Uchibori, Ken and Kitazono, Satoru and Yanagitani, Noriko and Nishio, Makoto},
title = {Clinical characteristics of patients with KRAS mutation detected by liquid biopsy},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15123}
}
EUVIMED